Cerebellar Astrocytoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cerebellar pilocytic astrocytoma (PA, WHO grade 1) is the most common pediatric cerebellar tumor and, after complete surgical resection, the most curable primary CNS tumor in children. It accounts for approximately 15-20% of all pediatric brain tumors and occurs predominantly between ages 5 and 15, arising in the cerebellar hemispheres, vermis, or the floor of the fourth ventricle. A smaller subset occurs in the brainstem (particularly dorsal exophytic brainstem glioma, a form of PA). Molecularly, the majority carry the BRAF-KIAA1549 tandem duplication fusion at 7q34 (~70%), which constitutively activates the MAPK/ERK signaling pathway. WHO grade 1 designation reflects a slow proliferative rate, with a Ki-67 index typically below 5%. Despite the WHO grade 1 designation, prognosis depends critically on achieving complete surgical resection.

Most cerebellar astrocytomas are sporadic with no identifiable hereditary cause. The BRAF-KIAA1549 fusion arising from a tandem duplication on chromosome 7q34 is the most common molecular alteration (~70%) and constitutively activates MAPK/ERK signaling to drive tumor growth. BRAF V600E point mutation identifies a subset with distinct behavior — more likely in adult and supratentorial PA — and may respond to BRAF plus MEK inhibitor combination therapy. Neurofibromatosis type 1 (NF1 germline mutation) significantly predisposes to pilocytic astrocytomas throughout the CNS including the optic pathway, brainstem, and cerebellum — NF1-associated PAs tend to be more indolent than sporadic cases. Other MAPK pathway alterations (NRAS, KRAS, FGFR1-TACC1 fusions) occur in a small minority of cases. No environmental risk factors for cerebellar astrocytoma are established.

Obstructive hydrocephalus from fourth ventricle compression produces the dominant symptoms: persistent morning headaches that may be positional (worse when supine), early morning or projectile vomiting, and progressive irritability in young children. Raised intracranial pressure causes papilledema, which may be detected on fundoscopy before other symptoms are apparent. Cerebellar hemisphere dysfunction produces ipsilateral limb ataxia, dysmetria (inability to accurately gauge distances during movement), dysdiadochokinesia (impaired rapid alternating movements), and intention tremor. Vermis involvement causes truncal ataxia with a wide-based unsteady gait. Sixth cranial nerve palsy from raised ICP causes diplopia. Nystagmus is common. Progression is typically over weeks to months. Acute neurological deterioration may follow intratumoral hemorrhage (rare) or sudden CSF flow obstruction.

MRI brain with and without gadolinium is the primary and definitive diagnostic investigation. The classic radiological appearance — present in approximately 60% of cases — is a cystic mass with a brightly enhancing mural nodule within the cyst wall; solid-enhancing and solid-cystic variants also occur. MRI of the complete craniospinal axis is performed to exclude leptomeningeal dissemination (uncommon in PA but important to document). Molecular testing on surgical tissue is now standard: BRAF-KIAA1549 fusion by FISH or RNA sequencing (most important); BRAF V600E by immunohistochemistry or sequencing; and DNA methylation profiling for definitive classification. Proton magnetic resonance spectroscopy (1H-MRS) helps differentiate PA from other posterior fossa tumors (PNET, ependymoma, DLBCL) before surgery. No specific tumor markers are available. NF1 germline testing is offered to all pediatric PA patients.

Gross total surgical resection (GTR) is the treatment of choice and is curative in the majority of patients — 10-year overall survival exceeds 90% after GTR. No adjuvant radiation or chemotherapy is required after complete resection of WHO grade 1 PA. Subtotally resected tumors are observed with serial MRI every 3-6 months initially, then annually — many remain stable for years without further intervention. Confirmed radiological progression: BRAF-KIAA1549 fusion-positive tumors respond to MEK inhibitors (selumetinib 25 mg/m2 BD or trametinib) with objective response rates of 30-40% and prolonged disease control. BRAF V600E-mutated tumors respond to dabrafenib plus trametinib combination. Second-line: carboplatin plus vincristine chemotherapy has been standard in children under 10 years to defer radiation. Radiotherapy (external beam or radiosurgery) is reserved for recurrent or progressive tumors not responding to chemotherapy or targeted therapy in older children, due to significant neurocognitive and endocrine late effects in young children.

Cerebellar pilocytic astrocytoma after complete gross total resection has an excellent prognosis — among the best of any primary brain tumor. Ten-year overall survival exceeds 90% after gross total resection (GTR), with approximately 94% of children achieving long-term cure. Subtotally resected tumors require careful MRI surveillance but do not invariably progress: approximately 50-70% of subtotally resected pilocytic astrocytomas remain stable for years without further intervention, and overall 10-year OS for all resected tumors (GTR and STR combined) exceeds 85%. Rare malignant transformation to higher-grade astrocytoma occurs in less than 1% and carries a significantly poorer prognosis. NF1-associated pilocytic astrocytomas tend to be more indolent than sporadic tumors, with many NF1-associated optic pathway and brainstem tumors exhibiting years of stability without progression. Tumor recurrence after initial GTR is uncommon — less than 10% at 10 years — and is often salvageable with reoperation or MEK inhibitor therapy. BRAF-KIAA1549 fusion predicts favorable prognosis and response to MEK inhibitors (selumetinib, trametinib) achieving objective response in 30-40% of unresectable or recurrent disease. Key prognostic factors include completeness of resection (the most important determinant), tumor location (cerebellar hemisphere versus fourth ventricle or brainstem), and NF1 status. Without treatment, progressive hydrocephalus and neurological deterioration will occur. MRI follow-up is recommended every 3-6 months for the first 2 years post-operatively, then annually for at least 5 years to detect recurrent or residual tumor before significant neurological progression develops.

Sporadic cerebellar pilocytic astrocytomas have no established modifiable risk factors and cannot currently be prevented. For individuals with neurofibromatosis type 1 (NF1), genetic counseling enables family members to understand their 50% inheritance risk, and cascade testing of at-risk relatives confirms NF1 status before tumor development. NF1-affected individuals should receive comprehensive annual neurological assessment and scheduled surveillance MRI of the brain and orbits, per NF1 clinical management guidelines, to detect CNS gliomas at asymptomatic stages when they are smallest and most surgically accessible. Avoidance of unnecessary ionizing radiation to the head reduces (but does not eliminate) risk of secondary brain tumors in NF1 patients. Gorlin syndrome (PTCH1) families should similarly receive specialist surveillance. Early detection through surveillance MRI enables resection before significant neurological deficit occurs.

Seek urgent medical evaluation for any child who develops: persistent headaches that are worst in the morning or disrupt sleep; unexplained vomiting not associated with gastroenteritis (especially projectile or non-nausea morning vomiting); unsteadiness, balance problems, or progressive clumsiness developing over weeks; squinting or double vision in a child; or head tilt that is new and persistent. These symptoms suggest posterior fossa pathology and require urgent brain MRI — do not wait for outpatient appointment if symptoms are progressive. Children known to have NF1 who develop any new neurological symptoms must be evaluated promptly and have any scheduled brain MRI surveillance completed on time. Parents should note that cerebellar astrocytoma symptoms typically progress over weeks to months, but deterioration can be rapid with acute hydrocephalus.